{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:42:48Z","timestamp":1771663368185,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Hereditary Disease Foundation Cure HD Initiative"},{"name":"CHDI Inc."},{"name":"PHS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular and Cellular Neuroscience"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.mcn.2011.10.007","type":"journal-article","created":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T02:20:40Z","timestamp":1319509240000},"page":"149-157","source":"Crossref","is-referenced-by-count":29,"title":["Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease"],"prefix":"10.1016","volume":"49","author":[{"given":"Miriam A.","family":"Hickey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunni","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Medvedeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas R.","family":"Franich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Fran\u00e7oise","family":"Chesselet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcn.2011.10.007_bb0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-7091-0579-5_13","article-title":"Coenzyme Q10 serum levels in Huntington's disease","author":"Andrich","year":"2004","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.mcn.2011.10.007_bb0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.mcn.2011.10.007_bb0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.brainresbull.2006.10.028","article-title":"Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease","volume":"72","author":"Aylward","year":"2007","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.mcn.2011.10.007_bb0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2010.208264","article-title":"Longitudinal change in regional brain volumes in prodromal Huntington disease","volume":"82","author":"Aylward","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.mcn.2011.10.007_bb0025","first-page":"1","article-title":"Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease","volume":"3","author":"Benn","year":"2008","journal-title":"BMC Mol. Neurodegeneration"},{"key":"10.1016\/j.mcn.2011.10.007_bb0030","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/10715760600617843","article-title":"Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics","volume":"40","author":"Bhagavan","year":"2006","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.mcn.2011.10.007_bb0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease","volume":"134","author":"Blazquez","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.mcn.2011.10.007_bb0040","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","article-title":"Normal huntingtin function: an alternative approach to Huntington's disease","volume":"6","author":"Cattaneo","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.mcn.2011.10.007_bb0045","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1196\/annals.1427.027","article-title":"Mitochondrial approaches for neuroprotection","volume":"1147","author":"Chaturvedi","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mcn.2011.10.007_bb0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","article-title":"Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochonrial dysfunction and neurodegeneration","volume":"127","author":"Cui","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.mcn.2011.10.007_bb0055","doi-asserted-by":"crossref","first-page":"10371","DOI":"10.1523\/JNEUROSCI.1592-09.2009","article-title":"Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease","volume":"29","author":"Cummings","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.mcn.2011.10.007_bb0060","doi-asserted-by":"crossref","first-page":"e00036","DOI":"10.1042\/AN20100007","article-title":"Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease","volume":"2","author":"Cummings","year":"2010","journal-title":"ASN Neuro"},{"key":"10.1016\/j.mcn.2011.10.007_bb0065","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/0028-3908(88)90071-8","article-title":"Regional distribution of ubiquinones and tocopherols in the mouse brain: lowest content of ubiquinols in the substantia nigra","volume":"27","author":"Fariello","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mcn.2011.10.007_bb0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/mds.870110317","article-title":"Assessment of coenzyme Q10 tolerability in Huntington's disease","volume":"11","author":"Feigin","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.mcn.2011.10.007_bb0075","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.mcn.2011.10.007_bb0080","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1212\/01.wnl.0000187070.35365.d7","article-title":"Tolerance of high-dose (3,000mg\/day) coenzyme Q10 in ALS","volume":"65","author":"Ferrante","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2011.10.007_bb0085","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.mcn.2011.10.007_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2005.01.024","article-title":"Early behavioral deficits in R6\/2 mice suitable for use in preclinical drug testing","volume":"20","author":"Hickey","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2011.10.007_bb0095","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuroscience.2008.08.041","article-title":"Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice","volume":"157","author":"Hickey","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.mcn.2011.10.007_bb0100","first-page":"752","article-title":"Mouse models of mental illness and neurological disease","volume":"32","author":"Hickey","year":"2011"},{"key":"10.1016\/j.mcn.2011.10.007_bb0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10094","article-title":"Environmental enrichment slows disease progression in R6\/2 Huntington's disease mice","volume":"51","author":"Hockly","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2011.10.007_bb0110","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2011.10.007_bb0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.nbd.2005.07.007","article-title":"Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease","volume":"21","author":"Hockly","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2011.10.007_bb0120","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1093\/jn\/133.10.3175","article-title":"Coenzyme Q intake elevates the mitochondrial and tissue levels of Coenzyme Q and alpha-tocopherol in young mice","volume":"133","author":"Kamzalov","year":"2003","journal-title":"J. Nutr."},{"key":"10.1016\/j.mcn.2011.10.007_bb0125","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1093\/hmg\/ddq306","article-title":"Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease","volume":"19","author":"Kim","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2011.10.007_bb0130","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1152\/jn.2001.86.6.2667","article-title":"Electrophysiological and morphological changes in striatal spiny neurons in R6\/2 Huntington's disease transgenic mice","volume":"86","author":"Klapstein","year":"2001","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.mcn.2011.10.007_bb0135","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.410410206","article-title":"Energy metabolism defects in Huntington's disease and effects of coenzyme Q10","volume":"41","author":"Koroshetz","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2011.10.007_bb0140","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0891-5849(02)00916-4","article-title":"Effects of coenzyme Q(10) administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat","volume":"33","author":"Kwong","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.mcn.2011.10.007_bb0145","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1371\/journal.pgen.0030135","article-title":"Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism","volume":"3","author":"Lee","year":"2007","journal-title":"PLoS Genet."},{"key":"10.1016\/j.mcn.2011.10.007_bb0150","doi-asserted-by":"crossref","first-page":"8892","DOI":"10.1073\/pnas.95.15.8892","article-title":"Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects","volume":"95","author":"Matthews","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mcn.2011.10.007_bb0155","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/exnr.1999.7327","article-title":"Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease","volume":"162","author":"Menalled","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2011.10.007_bb0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.mcn.2011.10.007_bb0165","doi-asserted-by":"crossref","first-page":"e9793","DOI":"10.1371\/journal.pone.0009793","article-title":"Comprehensive behavioral testing in the R6\/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline","volume":"5","author":"Menalled","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.mcn.2011.10.007_bb0170","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1523\/JNEUROSCI.0146-10.2010","article-title":"Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into Huntington's disease molecular pathogenesis","volume":"30","author":"Miller","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.mcn.2011.10.007_bb0175","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nm.2056","article-title":"Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin","volume":"15","author":"Okamoto","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcn.2011.10.007_bb0180","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.mcn.2011.10.007_bb0185","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.mcn.2011.10.007_bb0190","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/hmg\/ddn428","article-title":"Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models","volume":"18","author":"Phan","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2011.10.007_bb0195","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1111\/j.1460-9568.2004.03783.x","article-title":"Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation","volume":"20","author":"Ribchester","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.mcn.2011.10.007_bb0200","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/hmg\/8.5.813","article-title":"Formation of polyglutamine inclusions in non-CNS tissue","volume":"8","author":"Sathasivam","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2011.10.007_bb0205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0092-8674(00)81782-1","article-title":"Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions","volume":"95","author":"Saudou","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.mcn.2011.10.007_bb0210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","article-title":"Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model","volume":"315","author":"Schilling","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mcn.2011.10.007_bb0215","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.expneurol.2004.01.003","article-title":"Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice","volume":"187","author":"Schilling","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2011.10.007_bb0220","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1212\/WNL.50.3.793","article-title":"Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients","volume":"50","author":"Shults","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2011.10.007_bb0225","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.expneurol.2004.05.003","article-title":"Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease","volume":"188","author":"Shults","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2011.10.007_bb0230","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1073\/pnas.0811228106","article-title":"Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice","volume":"106","author":"Simmons","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2011.10.007_bb0235","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbadis.2006.03.004","article-title":"Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice","volume":"1762","author":"Smith","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mcn.2011.10.007_bb0240","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","article-title":"Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington's disease mice","volume":"1762","author":"Stack","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mcn.2011.10.007_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0020937","article-title":"Neurocognitive signs in prodromal Huntington disease","volume":"25","author":"Stout","year":"2011","journal-title":"Neuropsychology"},{"key":"10.1016\/j.mcn.2011.10.007_bb0250","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/hmg\/ddi192","article-title":"Gene expression in Huntington's disease skeletal muscle: a potential biomarker","volume":"14","author":"Strand","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2011.10.007_bb0255","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease","volume":"57","author":"The Huntington Study Group","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.mcn.2011.10.007_bb0260","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/mds.22408","article-title":"Safety and tolerability of high-dose coenzyme Q10 in Huntington's disease and healthy subjects","volume":"25","author":"The Huntington Study Group Pre2CARE Investigators","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.mcn.2011.10.007_bb0265","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"The Huntington's Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.mcn.2011.10.007_bb0270","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/mds.21540","article-title":"Clinical correlates of mitochondrial function in Huntington's disease muscle","volume":"22","author":"Turner","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.mcn.2011.10.007_bb0275","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/hmg\/ddq253","article-title":"Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease","volume":"19","author":"Underwood","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcn.2011.10.007_bb0280","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2007.07.029","article-title":"Increased metabolism in the R6\/2 mouse model of Huntington's disease","volume":"29","author":"van der Burg","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2011.10.007_bb0290","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmet.2006.10.004","article-title":"Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration","volume":"4","author":"Weydt","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.mcn.2011.10.007_bb0295","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","article-title":"Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases","volume":"109","author":"Yang","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2011.10.007_bb0305","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jn\/125.3.446","article-title":"Uptake of dietary coenzyme Q supplement is limited in rats","volume":"125","author":"Zhang","year":"1995","journal-title":"J. Nutr."},{"key":"10.1016\/j.mcn.2011.10.007_bb0310","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/jn\/126.9.2089","article-title":"Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of alpha-tocopherol into rat organs and cells","volume":"126","author":"Zhang","year":"1996","journal-title":"J. Nutr."}],"container-title":["Molecular and Cellular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104474311100248X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104474311100248X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:10:45Z","timestamp":1741849845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104474311100248X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S104474311100248X"],"URL":"https:\/\/doi.org\/10.1016\/j.mcn.2011.10.007","relation":{},"ISSN":["1044-7431"],"issn-type":[{"value":"1044-7431","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}